Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Orbus Therapeutics Inc.
Headquarters: Palo Alto, CA, United States of America
Website: http://www.orbustherapeutics...
Year Founded: 2012
Status: Private
BioCentury | Mar 1, 2025
Management Tracks
Orbus names co-founder, COO Levin president
Plus: Michael Bell becomes CTO of Chemify, and updates from Genbio AI and Epivax
BioCentury | Oct 24, 2020
Finance
Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris
New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies
BioCentury | Jul 28, 2016
Distillery Therapeutics
Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)
BioCentury | Aug 24, 2015
Finance
Making more music
Jazz roots helped Orbus raise series A for orphan play with generic candidate
Items per page:
1 - 8 of 8